1. Home
  2. HON vs VRTX Comparison

HON vs VRTX Comparison

Compare HON & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Honeywell International Inc.

HON

Honeywell International Inc.

HOLD

Current Price

$213.09

Market Cap

134.7B

Sector

Industrials

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$426.88

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
HON
VRTX
Founded
1885
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
134.7B
115.7B
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
HON
VRTX
Price
$213.09
$426.88
Analyst Decision
Buy
Buy
Analyst Count
13
29
Target Price
$249.92
$539.69
AVG Volume (30 Days)
3.2M
972.4K
Earning Date
04-23-2026
05-04-2026
Dividend Yield
2.26%
N/A
EPS Growth
N/A
836.54
EPS
1.29
4.02
Revenue
$36,529,000,000.00
$2,488,652,000.00
Revenue This Year
$6.74
$10.79
Revenue Next Year
$5.91
$10.47
P/E Ratio
$167.81
$105.87
Revenue Growth
12.92
46.20
52 Week Low
$186.76
$362.50
52 Week High
$248.18
$509.98

Technical Indicators

Market Signals
Indicator
HON
VRTX
Relative Strength Index (RSI) 40.83 42.58
Support Level $204.27 $403.16
Resistance Level $222.78 $428.73
Average True Range (ATR) 5.14 8.61
MACD 0.03 0.43
Stochastic Oscillator 23.98 47.71

Price Performance

Historical Comparison
HON
VRTX

About HON Honeywell International Inc.

Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: